Northern Trust Corp Fibrogen Inc Transaction History

Northern Trust Corp

  • $586 Billion
  • Q2 2024

A detailed history of Northern Trust Corp transactions in Fibrogen Inc stock. As of the latest transaction made, Northern Trust Corp holds 686,527 shares of FGEN stock, worth $281,476. This represents 0.0% of its overall portfolio holdings.

Number of Shares
686,527
Previous 756,491 9.25%
Holding current value
$281,476
Previous $1.78 Million 65.62%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$0.89 - $2.36 $62,267 - $165,115
-69,964 Reduced 9.25%
686,527 $611,000
Q1 2024

May 14, 2024
SELL
$0.73 - $2.73 $15,294 - $57,198
-20,952 Reduced 2.69%
756,491 $1.78 Million
Q4 2023

Feb 13, 2024
BUY
$0.38 - $0.91 $14,160 - $33,911
37,265 Added 5.03%
777,443 $691,000
Q3 2023

Nov 13, 2023
SELL
$0.79 - $2.83 $80,230 - $287,406
-101,557 Reduced 12.07%
740,178 $636,000
Q2 2023

Aug 11, 2023
BUY
$2.49 - $20.59 $13,846 - $114,500
5,561 Added 0.67%
841,735 $2.27 Million
Q1 2023

May 15, 2023
BUY
$15.95 - $25.18 $275,839 - $435,462
17,294 Added 2.11%
836,174 $15.6 Million
Q4 2022

Feb 13, 2023
BUY
$13.27 - $17.73 $271,663 - $362,968
20,472 Added 2.56%
818,880 $13.1 Million
Q3 2022

Nov 14, 2022
SELL
$11.4 - $14.6 $72,344 - $92,651
-6,346 Reduced 0.79%
798,408 $10.4 Million
Q2 2022

Aug 12, 2022
SELL
$7.94 - $12.96 $336,624 - $549,452
-42,396 Reduced 5.0%
804,754 $8.5 Million
Q1 2022

May 13, 2022
SELL
$12.02 - $16.79 $767,681 - $1.07 Million
-63,867 Reduced 7.01%
847,150 $10.2 Million
Q4 2021

Feb 08, 2022
BUY
$9.93 - $15.39 $375,185 - $581,480
37,783 Added 4.33%
911,017 $12.8 Million
Q3 2021

Nov 15, 2021
SELL
$10.18 - $26.64 $297,826 - $779,379
-29,256 Reduced 3.24%
873,234 $8.92 Million
Q2 2021

Aug 13, 2021
SELL
$18.57 - $35.68 $1.09 Million - $2.09 Million
-58,701 Reduced 6.11%
902,490 $24 Million
Q1 2021

May 12, 2021
SELL
$31.0 - $55.72 $2.53 Million - $4.55 Million
-81,576 Reduced 7.82%
961,191 $33.4 Million
Q4 2020

Feb 11, 2021
SELL
$37.09 - $48.97 $1.35 Million - $1.78 Million
-36,292 Reduced 3.36%
1,042,767 $38.7 Million
Q3 2020

Nov 16, 2020
BUY
$40.47 - $45.5 $657,354 - $739,056
16,243 Added 1.53%
1,079,059 $44.4 Million
Q2 2020

Aug 14, 2020
BUY
$32.57 - $42.83 $931,827 - $1.23 Million
28,610 Added 2.77%
1,062,816 $43.1 Million
Q1 2020

May 14, 2020
BUY
$23.3 - $45.96 $255,973 - $504,916
10,986 Added 1.07%
1,034,206 $35.9 Million
Q4 2019

Feb 14, 2020
SELL
$34.58 - $48.06 $336,325 - $467,431
-9,726 Reduced 0.94%
1,023,220 $43.9 Million
Q3 2019

Nov 13, 2019
BUY
$36.98 - $48.45 $1.4 Million - $1.83 Million
37,867 Added 3.81%
1,032,946 $38.2 Million
Q2 2019

Aug 13, 2019
BUY
$35.13 - $55.53 $2.01 Million - $3.18 Million
57,248 Added 6.1%
995,079 $45 Million
Q1 2019

May 13, 2019
BUY
$42.83 - $59.91 $802,848 - $1.12 Million
18,745 Added 2.04%
937,831 $51 Million
Q4 2018

Feb 12, 2019
BUY
$37.97 - $60.16 $76,813 - $121,703
2,023 Added 0.22%
919,086 $42.5 Million
Q3 2018

Nov 14, 2018
BUY
$56.3 - $67.25 $775,645 - $926,503
13,777 Added 1.53%
917,063 $55.7 Million
Q2 2018

Sep 18, 2018
SELL
$44.9 - $64.95 $228,002 - $329,816
-5,078 Reduced 0.56%
903,286 $56.5 Million
Q2 2018

Aug 14, 2018
BUY
$44.9 - $64.95 $3.48 Million - $5.03 Million
77,426 Added 9.32%
908,364 $56.9 Million
Q1 2018

May 09, 2018
SELL
$45.35 - $61.65 $283,074 - $384,819
-6,242 Reduced 0.75%
830,938 $38.4 Million
Q4 2017

Feb 14, 2018
BUY
$41.95 - $60.1 $519,047 - $743,617
12,373 Added 1.5%
837,180 $39.7 Million
Q3 2017

Nov 13, 2017
BUY
$33.4 - $53.9 $27.5 Million - $44.5 Million
824,807
824,807 $44.4 Million

Others Institutions Holding FGEN

# of Institutions
115
Shares Held
57.5M
Call Options Held
2.14M
Put Options Held
907K
View Full List

About FIBROGEN INC

FGEN Quotes by TradingView
  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $38.4M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email